Literature DB >> 20614504

Osteoporosis: Zoledronic acid for osteoporosis treatment--a matter of time.

Rowan Higgs.   

Abstract

Entities:  

Year:  2010        PMID： 20614504     DOI： 10.1038/nrrheum.2010.96

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Authors:  Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; David Kendler; Christina Bucci-Rechtweg; Aimee Readie; Peter Mesenbrink; Robert S Weinstein
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

2.  Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.

Authors:  Andrew Grey; Mark Bolland; Diana Wattie; Anne Horne; Greg Gamble; Ian R Reid
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.